Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is an experimental small molecule compound belonging to the phenylpiperazine class. It features a piperazine ring substituted with a methyl group and linked to a benzene ring, which is further connected via a diazene and carbothioamide moiety. The compound has been identified as targeting the protein S100B, which is implicated in various cellular processes including regulation of cell cycle progression and differentiation. There are no approved indications or clinical trials reported for this molecule as of now[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide.